These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2373040)

  • 1. [Erythropoietin in multiple myeloma].
    Pecherstorfer M; Schmoranzer F; Vesely M; Fortelny A; Baumgartner G
    Dtsch Med Wochenschr; 1990 Jul; 115(28-29):1096-9. PubMed ID: 2373040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
    Cohen AM; Meytes D; Many A; Brenner B; Aghai E; Shaklai M; Kaufman S; Shtalrid M; Attias D; Manor Y
    Isr J Med Sci; 1995 Oct; 31(10):604-10. PubMed ID: 7591683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.
    Ludwig H; Spicka I; Klener P; Greil R; Adam Z; Gisslinger H; Tarkovács G; Linkesch W; Maniatis A; Morant R; Drach J; Kuhn I; Schuster J; Hinke A
    Br J Haematol; 2005 Nov; 131(3):329-37. PubMed ID: 16225652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.
    Ludwig H; Cohen AM; Huber H; Nachbaur D; Jungi WF; Senn H; Günczler P; Schüller J; Eckhardt S; Seewann HL
    Eur J Cancer; 1991; 27 Suppl 4():S40-5. PubMed ID: 1799476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined alpha-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: a prospective randomized trial.
    Scheithauer W; Cortelezzi A; Fritz E; Kührer I; Polli E; Baldini L; Ludwig H
    J Biol Response Mod; 1989 Apr; 8(2):109-15. PubMed ID: 2659740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma.
    Preis P; Scheithauer W; Fritz E; Zielinski C; Kuehrer I; Cortelezzi A; Polli E; Baldini L; Pirker R; Kriegisch A
    Onkologie; 1989 Feb; 12(1):27-9. PubMed ID: 2654788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma.
    Kabir AL; Rahman MJ; Begum M; Dipta TF; Baqui MN; Aziz A; Rahman F; Debnath RC; Habib MA
    Mymensingh Med J; 2012 Jan; 21(1):114-9. PubMed ID: 22314465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
    Boccadoro M; Marmont F; Tribalto M; Avvisati G; Andriani A; Barbui T; Cantonetti M; Carotenuto M; Comotti B; Dammacco F
    J Clin Oncol; 1991 Mar; 9(3):444-8. PubMed ID: 1999714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden.
    Hjorth M; Hellquist L; Holmberg E; Magnusson B; Rödjer S; Westin J
    Br J Haematol; 1990 Feb; 74(2):185-91. PubMed ID: 2180471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].
    Montalbán C; Sevilla F; Zapatero A; Blanco L; Sabán J; Serrano M; Serrano Ríos M
    Rev Clin Esp; 1985 May; 176(8):392-5. PubMed ID: 3839590
    [No Abstract]   [Full Text] [Related]  

  • 11. A case of multiple myeloma with nuclear hypersegmentation after MP/VAD/VCAP-IFN therapies with a good prognosis.
    Nara M; Suzuki K; Inoue Y; Enomoto H; Saito T; Fujioka S
    Acta Haematol; 1993; 90(2):102-3. PubMed ID: 8285014
    [No Abstract]   [Full Text] [Related]  

  • 12. [Long-term osteoporosis with multiple fractures as the early monosymptomatic stage of multiple myeloma].
    Abbrederis K; Gattringer C; König P; Gastl G
    Onkologie; 1984 Jun; 7(3):152-5. PubMed ID: 6379533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Results of alternating treatment of multiple myeloma--cytostatics VBMCP and recombinant interferon alfa-2B].
    Gola A; Usnarska-Zubkiewicz L; Wołowiec D; Urbaniak-Kujda D; Kotlarek-Haus S
    Pol Arch Med Wewn; 1993 Aug; 90(2):134-41. PubMed ID: 8247946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol.
    Pileri A; Barbui T; Boccadoro M; Comotti B; Dammacco F; Gallamini A; Marmont F; Neretto G; Petrucci MT; Resegotti L
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():168-9. PubMed ID: 2713554
    [No Abstract]   [Full Text] [Related]  

  • 16. Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.
    Brugnatelli S; Riccardi A; Ucci G; Mora O; Barbarano L; Piva N; Piccinini L; Bergonzi C; De Paoli A; Di Stasi M; Rinaldi E; Trotti G; Petrini M; Ascari E
    Br J Cancer; 1996 Mar; 73(6):794-7. PubMed ID: 8611382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial.
    Ludwig H; Cortelezzi A; Scheithauer W; Van Camp BG; Kuzmits R; Fillet G; Peetermans M; Polli E; Flener R
    Eur J Cancer Clin Oncol; 1986 Sep; 22(9):1111-6. PubMed ID: 3536528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Results of polychemotherapy (a VMCP/VCAP program) in multiple myeloma].
    Wutke K; Anger G
    Z Gesamte Inn Med; 1983 Dec; 38(23):630-3. PubMed ID: 6689459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Plasmocytic pleural effusion disclosing multiple myeloma].
    Elloumi M; Frikha M; Masmoudi H; Mseddi S; Ben Ayed M; Bouaziz M; Makni F; Souissi T
    Rev Mal Respir; 2000 Apr; 17(2):495-7. PubMed ID: 10859769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Polychemotherapy versus melphalan-prednisone in multiple myeloma].
    Leoni P; Salvi A; Brianzoni MF; Centurioni R; Montillo M; Olivieri A
    G Clin Med; 1986 Dec; 67(5-6):291-6. PubMed ID: 3609590
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.